MX366852B - Conjugados de insulina sensibles a glucosa. - Google Patents

Conjugados de insulina sensibles a glucosa.

Info

Publication number
MX366852B
MX366852B MX2016004259A MX2016004259A MX366852B MX 366852 B MX366852 B MX 366852B MX 2016004259 A MX2016004259 A MX 2016004259A MX 2016004259 A MX2016004259 A MX 2016004259A MX 366852 B MX366852 B MX 366852B
Authority
MX
Mexico
Prior art keywords
glucose
saccharide
insulin conjugates
ligand
insulin
Prior art date
Application number
MX2016004259A
Other languages
English (en)
Other versions
MX2016004259A (es
Inventor
Ravi P Nargund
Zhiqiang Zhao
Dmitri Pissarnitski
Ahmet Kekec
Danqing Feng
Lin Yan
Lin Songnian
Zhu Yuping
n hunter David
Huo Pei
R Moyes Christopher
Pipik Brenda
N Guidry Erin
L Duffy Joseph
Original Assignee
Merck Sharp & Dohme
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp & Dohme filed Critical Merck Sharp & Dohme
Publication of MX2016004259A publication Critical patent/MX2016004259A/es
Publication of MX366852B publication Critical patent/MX366852B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/62—Insulins

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Se describen conjugados de insulina comprenden una molécula de insulina unida covalentemente a al menos un enlazador bidentado que tiene dos brazos, cada brazo está unido independientemente a un ligando que comprende un sacárido y en donde el sacárido de al menos un ligando del enlazador es fucosa; los conjugados de insulina presentan un perfil farmacocinético (PK) y/o un perfil farmacodinámico (PD) que es sensible a las concentraciones sistémicas de un sacárido tal como glucosa o alfa-metilmanosa incluso cuando se administran a un sujeto que lo necesita en ausencia de una molécula de unión a sacárido multivalente exógena tal como Con A.
MX2016004259A 2013-10-04 2014-10-02 Conjugados de insulina sensibles a glucosa. MX366852B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361886717P 2013-10-04 2013-10-04
PCT/US2014/058714 WO2015051052A2 (en) 2013-10-04 2014-10-02 Glucose-responsive insulin conjugates

Publications (2)

Publication Number Publication Date
MX2016004259A MX2016004259A (es) 2016-07-08
MX366852B true MX366852B (es) 2019-07-25

Family

ID=51794958

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016004259A MX366852B (es) 2013-10-04 2014-10-02 Conjugados de insulina sensibles a glucosa.

Country Status (13)

Country Link
US (3) US9427475B2 (es)
EP (1) EP3052134B1 (es)
JP (1) JP6491649B2 (es)
KR (1) KR20160065930A (es)
CN (1) CN105792852B (es)
AR (1) AR097893A1 (es)
AU (1) AU2014329567B2 (es)
BR (1) BR112016007176A2 (es)
CA (1) CA2924743A1 (es)
MX (1) MX366852B (es)
RU (1) RU2676307C2 (es)
TW (1) TW201605470A (es)
WO (1) WO2015051052A2 (es)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2791683T3 (es) * 2009-01-28 2020-11-05 Smartcells Inc Sistemas a base de conjugados para la administración controlada de fármacos
CA2924743A1 (en) 2013-10-04 2015-04-09 Merck Sharp & Dohme Corp. Glucose-responsive insulin conjugates
EP3119437B1 (en) 2014-03-21 2019-09-04 Genzyme Corporation Gene therapy for retinitis pigmentosa
CN108064173B (zh) * 2014-11-21 2021-05-18 默沙东公司 胰岛素受体部分激动剂
US20180110863A1 (en) * 2015-04-08 2018-04-26 Merck Sharp & Dohme Corp. Glucose-responsive insulin conjugates
EP3291828A4 (en) 2015-05-06 2018-10-03 Alborz Mahdavi Glucose responsive insulins
JP2018531900A (ja) 2015-08-25 2018-11-01 ノヴォ ノルディスク アー／エス 新規インスリン誘導体及びその医学的使用
US10946102B2 (en) 2016-01-14 2021-03-16 North Carolina State University Glucose responsive insulin delivery compositions and methods
EP3922260A3 (en) * 2016-05-24 2022-06-15 Merck Sharp & Dohme Corp. Insulin receptor partial agonists and glp-1 analogues
KR20190015413A (ko) 2016-06-02 2019-02-13 사노피 글루코오스 감지 단백질에 결합할 수 있는 모이어티 및 약제의 접합체
WO2018136505A1 (en) * 2017-01-17 2018-07-26 Wayne State University Zwitterionic polymer-insulin compositions and related methods
WO2018175272A1 (en) 2017-03-23 2018-09-27 Merck Sharp & Dohme Corp. Glucose responsive insulin comprising a tri-valent sugar cluster for treatment of diabetes
US20180318426A1 (en) * 2017-05-05 2018-11-08 Merck Sharp & Dohme Corp. Pharmaceutical formulations comprising insulin or insulin analogs conjugated to fucose for providing a basal pharmacodynamic profile
CN111032685A (zh) 2017-08-17 2020-04-17 诺沃挪第克公司 新型酰化胰岛素类似物及其用途
JP6874266B2 (ja) * 2017-09-22 2021-05-19 国立研究開発法人日本原子力研究開発機構 テトラアルキルニトリロ酢酸ジアセトアミド化合物の合成方法
WO2019075052A1 (en) * 2017-10-10 2019-04-18 North Carolina State University INSULIN MODIFIED BY GLUCOSE TRANSPORTER INHIBITOR FOR GLUCOSE SENSITIVE INSULIN ADMINISTRATION
KR20200095507A (ko) 2017-12-01 2020-08-10 사노피 글루코오스 감지 단백질에 결합할 수 있는 모이어티 및 약제의 신규 접합체
US11820805B2 (en) 2017-12-18 2023-11-21 Merck Sharp & Dohme Llc Conjugate based systems for controlled insulin delivery
US11413352B2 (en) 2017-12-18 2022-08-16 Merck, Sharp & Dohme LLC Conjugate based systems for controlled insulin delivery
US11530250B2 (en) 2018-03-22 2022-12-20 Merck Sharp & Dohme Llc Tyrosine-specific functionalized insulin and insulin analogs
WO2020247297A1 (en) * 2019-06-06 2020-12-10 Merck Sharp & Dohme Corp. Glucose-responsive insulin conjugates
US20220273770A1 (en) * 2019-07-30 2022-09-01 Merck Sharp & Dohme Corp. Glucose-responsive insulin conjugates
CA3159114A1 (en) 2019-12-11 2021-06-17 Frantisek Hubalek Novel insulin analogues and uses thereof
US20230104728A1 (en) * 2020-04-15 2023-04-06 Shenzhen Enduring Biotech, Ltd. Antibody-drug conjugate
JP2024510760A (ja) * 2021-03-19 2024-03-11 シェンチェン・エンデュアリング・バイオテック・リミテッド Ｃｄ３およびｃｄ１９に二重特異性を有するｐｅｇ化ｔ細胞エンゲージャー
WO2023091441A1 (en) * 2021-11-22 2023-05-25 Merck Sharp & Dohme Llc Glucose-responsive insulin conjugates comprising a tetra-valent sugar cluster for treatment of diabetes

Family Cites Families (109)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3591574A (en) 1968-05-29 1971-07-06 American Home Prod Tri-n-phenylglycyl derivatives of insulin
DE1793517C3 (de) 1968-09-28 1974-12-05 Farbwerke Hoechst Ag, Vormals Meister Lucius & Bruening, 6000 Frankfurt N(Al),N(B29>Bis-(tert.-butyloxycarbonyl)-insulin und Verfahren zu seiner Herstellung
US3847890A (en) 1971-11-01 1974-11-12 A Green Acidic monosaccharide-substituted proteins
US4086257A (en) 1976-10-12 1978-04-25 Sears Barry D Phosphatidyl quaternary ammonium compounds
EP0009842B1 (en) 1978-10-02 1982-11-10 THE PROCTER & GAMBLE COMPANY Liposomes for drug delivery and composition containing a liposome drug system
US4377567A (en) 1978-10-02 1983-03-22 The Procter & Gamble Company Lipid membrane drug delivery
US4348387A (en) 1979-07-31 1982-09-07 The Rockefeller University Method and system for the controlled release of biologically active substances to a body fluid
JPS608000B2 (ja) 1980-04-11 1985-02-28 呉羽化学工業株式会社 アミノフエニル誘導体及び該誘導体を含有する生理活性剤
US4444683A (en) 1982-11-17 1984-04-24 University Of Utah Glycosylated insulin derivatives
US4603044A (en) 1983-01-06 1986-07-29 Technology Unlimited, Inc. Hepatocyte Directed Vesicle delivery system
EP0119650A3 (en) 1983-03-21 1987-09-30 THE PROCTER & GAMBLE COMPANY Galactosyl-insulin conjugates useful in treating diabetics
US4863896A (en) 1984-05-03 1989-09-05 Technology Unlimited, Inc. Diabetic control by combined insulin forms
US5395924A (en) 1986-03-20 1995-03-07 Dana-Farber Cancer Institute, Inc. Blocked lectins; methods and affinity support for making the same using affinity ligands; and method of killing selected cell populations having reduced non-selective cytotoxicity
US5239062A (en) 1986-03-20 1993-08-24 Dana-Farber Cancer Institute, Inc. Blocked lectins, methods and affinity support for making same using affinity ligands, and method of killing selected cell populations having reduced nonselective cytotoxicity
US5527524A (en) 1986-08-18 1996-06-18 The Dow Chemical Company Dense star polymer conjugates
DK111489D0 (da) 1989-03-08 1989-03-08 Novo Nordisk As Peptider
AU628674B2 (en) 1989-10-19 1992-09-17 Nippon Oil And Fats Company, Limited Polymer complexes of a sugar response type
IL99699A (en) 1990-10-10 2002-04-21 Autoimmune Inc Drug with the option of oral, intra-intestinal, or inhaled dosing for suppression of autoimmune response associated with type I diabetes
US5304473A (en) 1991-06-11 1994-04-19 Eli Lilly And Company A-C-B proinsulin, method of manufacturing and using same, and intermediates in insulin production
GB9200638D0 (en) 1992-01-10 1992-03-11 Leicester Polytechnic Drug system
ES2145044T3 (es) 1992-02-13 2000-07-01 Surmodics Inc Inmovilizacion de especies quimicas en matrices reticuladas.
GB9316895D0 (en) 1993-08-13 1993-09-29 Guy S And St Thomas Hospitals Hepatoselective insulin analogues
GB9313484D0 (en) 1993-06-30 1993-08-11 Univ Montfort Drug system ii
US6342225B1 (en) 1993-08-13 2002-01-29 Deutshces Wollforschungsinstitut Pharmaceutical active conjugates
US6869930B1 (en) 1993-09-17 2005-03-22 Novo Nordisk A/S Acylated insulin
WO1995016708A1 (en) 1993-12-17 1995-06-22 Novo Nordisk A/S Proinsulin-like compounds
US5461031A (en) 1994-06-16 1995-10-24 Eli Lilly And Company Monomeric insulin analog formulations
US6500645B1 (en) 1994-06-17 2002-12-31 Novo Nordisk A/S N-terminally extended proteins expressed in yeast
US5693609A (en) 1994-11-17 1997-12-02 Eli Lilly And Company Acylated insulin analogs
IL118127A0 (en) 1995-05-05 1996-09-12 Lilly Co Eli Single chain insulin with high bioactivity
US5902603A (en) 1995-09-14 1999-05-11 Cygnus, Inc. Polyurethane hydrogel drug reservoirs for use in transdermal drug delivery systems, and associated methods of manufacture and use
TW520293B (en) 1995-11-22 2003-02-11 Univ Johns Hopkins Med Delivery system to enhance cellular uptake of biomolecules
US5723589A (en) 1995-12-21 1998-03-03 Icn Pharmaceuticals Carbohydrate conjugated bio-active compounds
US5866538A (en) 1996-06-20 1999-02-02 Novo Nordisk A/S Insulin preparations containing NaCl
US5948751A (en) 1996-06-20 1999-09-07 Novo Nordisk A/S X14-mannitol
US5905140A (en) 1996-07-11 1999-05-18 Novo Nordisk A/S, Novo Alle Selective acylation method
EP0954589A1 (en) 1997-01-24 1999-11-10 Novo Nordisk A/S Synthetic leader peptide sequences
CO4750643A1 (es) 1997-06-13 1999-03-31 Lilly Co Eli Formulacion estable de la insulina que contiene l-arginina y protamina
US6180757B1 (en) 1998-04-15 2001-01-30 Novo Nordisk A/S Process for the separation of proteins using a CA++ containing eluant
US6844166B1 (en) 1998-09-11 2005-01-18 Sensor Technologies Inc. Recombinant reduced valency carbohydrate binding ligands
US6323311B1 (en) 1999-09-22 2001-11-27 University Of Utah Research Foundation Synthesis of insulin derivatives
US6521738B2 (en) 1999-12-29 2003-02-18 Novo Nordisk A/S Method for making insulin precursors and insulin precursor analogs
US6777207B2 (en) 1999-12-29 2004-08-17 Novo Nordisk A/S Method for making insulin precursors and insulin precursor analogues having improved fermentation yield in yeast
AU2001263775A1 (en) 2000-06-02 2001-12-11 Novo-Nordisk A/S Glucose dependent release of insulin from glucose sensing insulin derivatives
US7316999B2 (en) 2000-06-02 2008-01-08 Novo Nordisk A/S Glucose dependent release of insulin from glucose sensing insulin derivatives
US20020068295A1 (en) 2000-07-13 2002-06-06 Marc Madou Multimeric biopolymers as structural elements and sensors and actuators in microsystems
KR100449454B1 (ko) 2000-10-02 2004-09-21 이현철 단일사슬 인슐린 유도체의 유전자를 포함하는 당뇨병치료용 벡터
US7060675B2 (en) 2001-02-15 2006-06-13 Nobex Corporation Methods of treating diabetes mellitus
AU2002258490A1 (en) 2001-03-12 2003-06-17 Clemson University Polysaccharide-based polmerizable hydrogels
US7105314B2 (en) 2001-04-02 2006-09-12 Novo Nordisk A/S Method for making human insulin precursors
CN101724075B (zh) 2001-10-10 2014-04-30 诺和诺德公司 肽的重构和糖缀合
US7311892B2 (en) 2001-10-26 2007-12-25 The Uab Research Foundation Multidrug multiligand conjugates for targeted drug delivery
US7473680B2 (en) 2001-11-28 2009-01-06 Neose Technologies, Inc. Remodeling and glycoconjugation of peptides
US7317000B2 (en) 2001-12-02 2008-01-08 Novo Nordisk A/S Glucose-dependent insulins
US7349688B2 (en) 2001-12-07 2008-03-25 Ntt Docomo, Inc. Mobile communications terminal, application program execution state control method, and execution state control computer program product
DE10209821A1 (de) 2002-03-06 2003-09-25 Biotechnologie Ges Mittelhesse Kopplung von Proteinen an ein modifiziertes Polysaccharid
WO2004009665A2 (en) 2002-07-19 2004-01-29 The Regents Of The University Of California Dendrimers as molecular translocators
CA2509382A1 (en) 2002-12-17 2004-07-08 Todd C. Zion Stimuli-responsive systems for controlled drug delivery
CA2549932C (en) 2002-12-20 2013-08-20 Greenovation Biotech Gmbh Production of heterologous glycosylated proteins in bryophyte cells
JPWO2004101619A1 (ja) 2003-05-15 2006-10-26 塩野義製薬株式会社 機能的糖ペプチドの合理的設計および合成
CN102816228A (zh) 2003-12-03 2012-12-12 诺和诺德公司 单链胰岛素
US20080102114A1 (en) 2004-04-23 2008-05-01 Panduranga Rao Koritala Microparticles and Nanoparticles for the Transmucosal Delivery of Therapeutic and Diagnostic Agents
WO2006008238A1 (en) 2004-07-16 2006-01-26 Novo Nordisk A/S Method for selective acylation
AU2005269753B2 (en) 2004-07-19 2011-08-18 Biocon Limited Insulin-oligomer conjugates, formulations and uses thereof
WO2006062685A2 (en) 2004-11-11 2006-06-15 Affymax, Inc. Novel peptides that bind to the erythropoietin receptor
TWI376234B (en) 2005-02-01 2012-11-11 Msd Oss Bv Conjugates of a polypeptide and an oligosaccharide
US20070207498A1 (en) 2005-02-24 2007-09-06 Lifescan, Inc. Design and construction of dimeric concanavalin a mutants
US20060247154A1 (en) 2005-02-24 2006-11-02 Lifescan, Inc. Concanavalin a, methods of expressing, purifying and characterizing concanavalina, and sensors including the same
EP1863840A1 (en) 2005-03-18 2007-12-12 Novo Nordisk A/S Pegylated single-chain insulin
US7517856B2 (en) 2005-10-11 2009-04-14 Ben-Gurion University Of The Negev Research And Development Authority Bioconjugates comprising sulfated polysaccharides and their uses
US7687608B2 (en) 2005-10-19 2010-03-30 Smartcells, Inc. Methods for reducing the mitogenicity of lectin compositions
JP2009527526A (ja) 2006-02-21 2009-07-30 ノボ・ノルデイスク・エー／エス 単鎖インスリンのアナログとその製薬的製剤
US8722620B2 (en) 2006-02-27 2014-05-13 Novo Nordisk A/S Insulin derivatives
US20090099065A1 (en) 2006-03-13 2009-04-16 Novo Nordisk A/S Acylated Single Chain Insulin
US20090069215A1 (en) 2006-03-13 2009-03-12 Novo Nordisk A/S Acylated Single Chain Insulin
WO2007104734A1 (en) 2006-03-13 2007-09-20 Novo Nordisk A/S Acylated single chain insulin
WO2007104736A2 (en) 2006-03-13 2007-09-20 Novo Nordisk A/S Acylated single chain insulin
WO2008036147A2 (en) 2006-07-24 2008-03-27 Duke University Drug delivery with stimulus responsive biopolymers
EP2041167B1 (en) 2006-07-25 2010-05-12 Lipoxen Technologies Limited Derivatisation of granulocyte colony-stimulating factor
FR2904315B1 (fr) 2006-07-26 2012-12-14 Centre Nat Rech Scient Composes pyridaziniques et pyrroliques, procedes d'obtention et applications
US9505823B2 (en) 2006-08-07 2016-11-29 TEV A Biopharmaceuticals USA, Inc. Albumin-insulin fusion proteins
CN101273961A (zh) 2007-03-30 2008-10-01 中国人民解放军总医院 葡萄糖敏感水凝胶
US20090053167A1 (en) 2007-05-14 2009-02-26 Neose Technologies, Inc. C-, S- and N-glycosylation of peptides
WO2009033588A2 (en) 2007-09-11 2009-03-19 F. Hoffmann-La-Roche Ag Self-controlled insulin delivery system
WO2009059450A1 (en) 2007-11-05 2009-05-14 Shanghai Jiaotong University Peptide ligand directed drug delivery
JP5647899B2 (ja) 2008-01-08 2015-01-07 ラツィオファルム ゲーエムベーハーｒａｔｉｏｐｈａｒｍ ＧｍｂＨ オリゴサッカリルトランスフェラーゼを使用するポリペプチドの複合糖質化
US20110065633A1 (en) 2008-01-30 2011-03-17 Indiana University Research And Technology Corporation Ester-based peptide prodrugs
RU2381238C2 (ru) 2008-01-31 2010-02-10 Ордена Трудового Красного Знамени Институт нефтехимического синтеза им. А.В. Топчиева Российской академии наук (статус государственного учреждения) Способ получения глюкозочувствительных полимерных гидрогелей
RU2495131C2 (ru) 2008-02-19 2013-10-10 Байокон Лимитид Способ получения рекомбинантного инсулина гларгина
KR20110021758A (ko) 2008-04-22 2011-03-04 케이스 웨스턴 리저브 유니버시티 이형체-특이적 인슐린 유사체
WO2010008060A1 (ja) 2008-07-17 2010-01-21 本田技研工業株式会社 車両用エアバッグとその製造方法
CA2747720A1 (en) 2008-12-19 2010-07-15 Indiana University Research And Technology Corporation Yl-based insulin-like growth factors exhibiting high activity at the insulin receptor
CA2744558A1 (en) 2008-12-19 2010-07-15 Indiana University Research And Technology Corporation Amide-based insulin prodrugs
US8603529B2 (en) 2009-01-28 2013-12-10 Smartcells, Inc. Polynucleotide aptamer-based cross-linked materials and uses thereof
ES2791683T3 (es) * 2009-01-28 2020-11-05 Smartcells Inc Sistemas a base de conjugados para la administración controlada de fármacos
JP2012516339A (ja) 2009-01-28 2012-07-19 スマートセルズ・インコーポレイテツド 外因的刺激型制御放出物質体およびその使用
KR20110110253A (ko) * 2009-01-28 2011-10-06 스마트쎌스, 인크. 결정질 인슐린-접합체
CA2750252A1 (en) * 2009-01-28 2010-08-05 Smartcells, Inc. Synthetic conjugates and uses thereof
CA2750115A1 (en) 2009-01-28 2010-08-05 Smartcells, Inc. Binding-site modified lectins and uses thereof
US8569231B2 (en) 2009-03-20 2013-10-29 Smartcells, Inc. Soluble non-depot insulin conjugates and uses thereof
EP2408808A4 (en) 2009-03-20 2015-05-06 Smartcells Inc TERMINAL-FUNCTIONALIZED CONJUGATES AND THEIR USE
EP2448962B1 (en) 2009-06-30 2016-10-19 Novo Nordisk A/S Insulin derivatives
AU2011282983A1 (en) 2010-07-28 2013-02-21 Smartcells, Inc. Drug-ligand conjugates, synthesis thereof, and intermediates thereto
AU2011282977A1 (en) 2010-07-28 2013-02-21 Smartcells, Inc. Drug-ligand conjugates, synthesis thereof, and intermediates thereto
CA2805902A1 (en) 2010-07-28 2012-02-02 Smartcells, Inc. Recombinant lectins, binding-site modified lectins and uses thereof
WO2012050822A1 (en) 2010-10-14 2012-04-19 Smartcells, Inc. Uses of macrophage mannose receptor to screen compounds and uses of these compounds
US8745838B2 (en) 2011-06-23 2014-06-10 Deere & Company Ball joint assembly for attaching cutting unit to yoke
AR087433A1 (es) 2011-08-08 2014-03-26 Merck Sharp & Dohme Analogos de insulina n-glicosilados
CA2924743A1 (en) 2013-10-04 2015-04-09 Merck Sharp & Dohme Corp. Glucose-responsive insulin conjugates

Also Published As

Publication number Publication date
US9427475B2 (en) 2016-08-30
US20150105317A1 (en) 2015-04-16
EP3052134B1 (en) 2021-05-05
EP3052134A2 (en) 2016-08-10
JP6491649B2 (ja) 2019-03-27
AU2014329567A1 (en) 2016-04-07
AR097893A1 (es) 2016-04-20
BR112016007176A2 (pt) 2018-01-23
CN105792852A (zh) 2016-07-20
JP2016533348A (ja) 2016-10-27
AU2014329567B2 (en) 2019-07-25
WO2015051052A2 (en) 2015-04-09
RU2016116513A (ru) 2017-11-09
CN105792852B (zh) 2019-12-10
US20160303244A1 (en) 2016-10-20
MX2016004259A (es) 2016-07-08
CA2924743A1 (en) 2015-04-09
RU2676307C2 (ru) 2018-12-27
US9889205B2 (en) 2018-02-13
WO2015051052A3 (en) 2015-07-02
RU2016116513A3 (es) 2018-06-28
TW201605470A (zh) 2016-02-16
KR20160065930A (ko) 2016-06-09
US9884125B2 (en) 2018-02-06
US20160251407A1 (en) 2016-09-01

Similar Documents

Publication Publication Date Title
MX2016004259A (es) Conjugados de insulina sensibles a glucosa.
AU2020202093A1 (en) Oligonucleotide-ligand conjugates and process for their preparation
EA201170986A1 (ru) Системы на основе конъюгатов для контролируемой доставки лекарственных средств
EP4253395A3 (en) Processes for the preparation of carbohydrate conjugated rna agents
MX2021010192A (es) Enlazadores de carbamato de metileno para su uso en conjugados de farmacos dirigidos.
WO2009130602A3 (en) Factor ix conjugates with extended half-lives
NZ758050A (en) Pegylated drug-linkers for improved ligand-drug conjugate pharmacokinetics
MY175421A (en) Compositiion for treating diabetes mellitus comprising insulin and a glp - 1/glucagon dual agonist
MY183572A (en) Biologically active molecules, conjugates thereof, and therapeutic uses
JP2015512531A5 (es)
WO2019125879A3 (en) Conjugate based systems for controlled insulin delivery
WO2012079030A3 (en) Bioconjugation using bifunctional linkers
FR2969980B1 (fr) Bicyclette pliable
NZ709620A (en) Pharmaceutical formulation comprising an insoluble corticosteroid and a soluble corticosteroid
CL2015003580A1 (es) Conjugados de suministro de polinucleotidos in vivo que tienen acoplamientos sensibles a enzima.
PH12020550105A1 (en) Long-acting conjugates of glp-2 derivatives
WO2013181597A3 (en) Thiol-ene click chemistry for drug conjugates
UA115811C2 (uk) Стабільний розчин об'єднаних баклофену, сорбіту і налтрексону для перорального застосування
WO2010045281A3 (en) Stable aqueous formulations of water insoluble or poorly soluble drugs
WO2012131378A3 (en) Pharmaceutical preparation comprising alpha emitting radionuclide
WO2013142596A3 (en) Shelf gap spacer device for a merchandise display system
MX2012006555A (es) Exhibidor auto-ajustable de posicion.
CN203859951U (zh) 便携式电子产品
WO2014083403A3 (en) Standing tape dispenser
EP3694539A4 (en) GLUCOSE CARRIER INHIBITOR MODIFIED INSULIN FOR THE DELIVERY OF GLUCOSE SENSITIVE INSULIN

Legal Events

Date Code Title Description
FG Grant or registration